Clinical Trial

A Phase I First-in-Human Study of GenSci128 in Patients With Solid Tumors Harboring a TP53 Y220C Mutation

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this study is to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of GenSci128 Tablet in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-03-26.
Status change: Not Yet Recruiting → Recruiting 2025-12-23
Trial Details
NCT Number NCT06908434
Lead Sponsor Changchun GeneScience Pharmaceutical Co., Ltd.
Conditions Solid Tumors Harboring a TP53 Y220C Mutation
Enrollment 82 participants
Start Date 2025-06-10
Primary Completion 2027-12 (estimated)
Study Completion 2028-10 (estimated)
Updated on ClinicalTrials.gov 2025-12-30